5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde CAS 881674-56-2 Vonoprazan Fumarate Intermediate Purity ≥99.0%

Short Description:

Name: 5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde

CAS: 881674-56-2

Purity: ≥99.0%    

Appearance: Yellow to Brown Powder

Intermediate of Vonoprazan Fumarate (CAS: 1260141-27-2)

High Quality, Commercialized Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde
Synonyms Vonoprazan Fumarate (TAK-438) Intermediate 3
CAS Number 881674-56-2
CAT Number RF-PI330
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C11H8FNO
Molecular Weight 189.19
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Yellow to Brown Powder
Melting Point 122.0~131.0℃  
Identification: RT(HPLC) Conform With The Reference Standard
Loss On Drying ≤0.50%
Residue On Ignition ≤0.50%
Related Substances
Purity ≥99.0% 
Any Single Impurity ≤0.50%
Total Impurities ≤1.0%
Test Standard Enterprise Standard
Usage Intermediate of Vonoprazan Fumarate (TAK-438) (CAS 881681-01-2)

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

5-(2-Fluorophenyl)-1H-Pyrrole-3-Carbaldehyde (CAS 881674-56-2) acts as a reagent in the synthetic preparation of novel pyrrole derivatives as potassium-competitive acid blocker (P-CAB). 5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde is the intermediate of Vonoprazan Fumarate (CAS 1260141-27-2). Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.

  • Write your message here and send it to us